14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:XLRN
Delisted

Acceleron Pharma Inc. Stock Price (Quote)

$178.75
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $141.16 $183.01 Friday, 27th May 2022 XLRN stock ended at $178.75. During the day the stock fluctuated 0% from a day low at $178.75 to a day high of $178.75.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Acceleron Pharma Inc. prices

Date Open High Low Close Volume
Mar 22, 2021 $137.86 $146.15 $136.17 $143.64 518 046
Mar 19, 2021 $134.50 $139.22 $133.49 $138.01 723 377
Mar 18, 2021 $135.71 $137.08 $132.60 $133.58 252 837
Mar 17, 2021 $135.95 $138.24 $134.36 $136.88 316 050
Mar 16, 2021 $139.14 $142.00 $135.73 $137.70 225 004
Mar 15, 2021 $136.88 $140.59 $136.88 $138.99 256 859
Mar 12, 2021 $135.00 $138.26 $133.08 $137.56 300 494
Mar 11, 2021 $129.90 $134.52 $129.60 $133.46 292 461
Mar 10, 2021 $131.22 $131.77 $128.07 $128.94 358 326
Mar 09, 2021 $129.93 $133.12 $128.53 $128.76 341 772
Mar 08, 2021 $128.39 $132.11 $125.09 $126.21 549 908
Mar 05, 2021 $127.06 $128.58 $119.20 $127.79 986 719
Mar 04, 2021 $129.57 $131.14 $126.52 $127.90 422 499
Mar 03, 2021 $136.15 $137.08 $128.97 $130.27 351 313
Mar 02, 2021 $140.44 $140.44 $134.60 $135.85 417 004
Mar 01, 2021 $138.61 $144.26 $137.90 $140.15 334 644
Feb 26, 2021 $122.99 $138.39 $122.99 $136.16 606 628
Feb 25, 2021 $136.76 $138.19 $133.80 $135.87 256 989
Feb 24, 2021 $136.65 $138.30 $133.07 $136.78 194 268
Feb 23, 2021 $138.31 $140.78 $133.12 $137.43 364 647
Feb 22, 2021 $133.09 $143.62 $132.19 $141.39 496 536
Feb 19, 2021 $129.94 $135.58 $127.67 $134.72 218 166
Feb 18, 2021 $127.96 $130.35 $124.58 $129.18 193 516
Feb 17, 2021 $126.35 $128.32 $122.51 $128.28 267 103
Feb 16, 2021 $131.13 $131.69 $125.49 $126.76 189 890
Click to get the best stock tips daily for free!

About Acceleron Pharma Inc.

Acceleron Pharma. Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It is developing sotatercept to treat patients with chronic kidney disease, including mineral-bone disorder, vascular calcification, and anemia; and luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassem... XLRN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT